Abstract
Mutations of the ADAR1 gene encoding an RNA deaminase cause severe diseases associated with chronic activation of type I interferon (IFN) responses, including Aicardi–Goutières syndrome and bilateral striatal necrosis1–3. The IFN-inducible p150 isoform of ADAR1 contains a Zα domain that recognizes RNA with an alternative left-handed double-helix structure, termed Z-RNA4,5. Hemizygous ADAR1 mutations in the Zα domain cause type I IFN-mediated pathologies in humans2,3 and mice6–8; however, it remains unclear how the interaction of ADAR1 with Z-RNA prevents IFN activation. Here we show that Z-DNA-binding protein 1 (ZBP1), the only other protein in mammals known to harbour Zα domains9, promotes type I IFN activation and fatal pathology in mice with impaired ADAR1 function. ZBP1 deficiency or mutation of its Zα domains reduced the expression of IFN-stimulated genes and largely prevented early postnatal lethality in mice with hemizygous expression of ADAR1 with mutated Zα domain (Adar1mZα/– mice). Adar1mZα/– mice showed upregulation and impaired editing of endogenous retroelement-derived complementary RNA reads, which represent a likely source of Z-RNAs activating ZBP1. Notably, ZBP1 promoted IFN activation and severe pathology in Adar1mZα/– mice in a manner independent of RIPK1, RIPK3, MLKL-mediated necroptosis and caspase-8-dependent apoptosis, suggesting a novel mechanism of action. Thus, ADAR1 prevents endogenous Z-RNA-dependent activation of pathogenic type I IFN responses by ZBP1, suggesting that ZBP1 could contribute to type I interferonopathies caused by ADAR1 mutations.
Subject terms: RIG-I-like receptors, Cell death and immune response
ADAR1 prevents Z-RNA-dependent activation of pathogenic type I interferon responses by ZBP1, whose activity may contribute to pathology in type I interferonopathies with ADAR1 mutations.
Main
Z-DNA and Z-RNA are nucleic acids with an alternative left-handed double-helix structure and have poorly understood biological function10–13. These Z-form nucleic acids are recognized by specific protein domains, termed Zα domains, which bind Z-DNA and Z-RNA in a conformation-specific manner5,9,14,15. Two proteins are known to harbour Zα domains in mammals, namely adenosine deaminase acting on RNA 1 (ADAR1) and Z-DNA-binding protein 1 (ZBP1, also known as DAI or DLM-1)5,9,14. ADAR1 is produced in two isoforms, the constitutively expressed nuclear p110 and the interferon (IFN)-inducible cytosolic p150 that contains a Zα domain1. ADAR1 p150 edits self-RNA derived predominantly from endogenous retroelements (EREs) to prevent its recognition by the cytosolic RNA sensor melanoma differentiation-associated gene 5 (MDA5) and the activation of mitochondrial antiviral signalling (MAVS)-dependent pathogenic type I IFN responses16–19. ADAR1 mutations mapping to the Zα domain combined with alleles resulting in loss of ADAR1 or specifically its p150 isoform were shown to cause Aicardi–Goutières syndrome (AGS) and bilateral striatal necrosis (BSN) in human patients2,3 and severe MDA5–MAVS-mediated type I IFN-dependent pathology in mice6–8, indicating that the interaction of ADAR1 with Z-RNA is required to prevent activation of pathogenic IFN responses. ZBP1 is an IFN-inducible protein that senses viral and endogenous Z-form nucleic acids via its Zα domains and triggers cell death to induce antiviral immunity, but also causes tissue damage and inflammation20–27. Previous studies have shown that ZBP1 causes cell death in vivo and in vitro by activating receptor-interacting protein kinase 3 (RIPK3) in a RIP homotypic interaction motif (RHIM)-dependent manner, which then phosphorylates mixed-lineage kinase-like (MLKL) to induce necroptosis and can also engage RIPK1 to trigger caspase-8-dependent apoptosis20,21,23,25,27. We reasoned that ZBP1 may functionally interact with ADAR1 to regulate cellular responses to Z-RNA and assessed its role in the activation of type I IFN-dependent pathology in mice with Adar1 mutations.
ADAR1 Zα domain inactivation induces IFN responses
To address the role of the ADAR1 Zα domain, we generated knock-in mice expressing ADAR1 with two substitutions disrupting its interaction with Z-RNA (N175D/Y179A)28,29 (Extended Data Fig. 1a), hereafter referred to as Adar1mZα/mZα mice. Adar1mZα/mZα mice were born at the expected Mendelian ratio, were viable and fertile and did not develop apparent pathology at least until the age of 1 year (Extended Data Fig. 1b–d). However, RNA sequencing (RNA-seq) showed upregulation of 57 genes in lung tissues from 4- to 5-month-old Adar1mZα/mZα mice, all of which were functionally linked to type I IFN responses, compared with Adar1mZα/WT and wild-type C57BL/6N animals (Extended Data Fig. 1e and Supplementary Table 1). Quantitative PCR with reverse transcription (qRT–PCR) analysis confirmed upregulation of a selected set of IFN-stimulated genes (ISGs) in lung, spleen and liver tissue from Adar1mZα/mZα mice compared with control littermates (Extended Data Fig. 1f). Therefore, disruption of the ADAR1 Zα domain caused elevated expression of ISGs in the absence of overt tissue pathology, in line with recent reports6,7,30. Mutations affecting the ADAR1 Zα domain were found to cause AGS and BSN when combined with alleles resulting in loss of ADAR1 p150 expression3,31. To model this condition, we generated Adar1mZα/– mice and foundthat they developed a severe phenotype characterized by reduced body weight and early postnatal lethality (Fig. 1a,b). Haematological analysis at postnatal day (P) 1 showed reduced numbers of red blood cells (RBCs) as well as diminished haemoglobin (HGB) and haematocrit (HCT) levels in Adar1mZα/– mice compared with Adar1mZα/WT mice (Fig. 1c), in line with the important role of ADAR1 in erythropoiesis32. Histological examination showed altered architecture with increased numbers of epithelial cells immunostained for cleaved caspase-3 (CC3) in the small intestine and colon of Adar1mZα/– pups, whereas other organs including the liver, lung, heart, kidney and brain did not show prominent pathological features (Fig. 1d and Extended Data Fig. 2a–d). RNA-seq analysis of lung, brain and spleen showed increased expression of several genes in Adar1mZα/– mice compared with Adar1mZα/WT littermates, the majority of which were linked to type I IFN responses (Extended Data Fig. 3 and Supplementary Table 2). Comparison of RNA-seq data from lung, brain and spleen identified a set of 93 genes, all ISGs, that were consistently upregulated in all three tissues from Adar1mZα/– compared with Adar1mZα/WT mice (Supplementary Table 2). A smaller number of genes were downregulated in Adar1mZα/– mice, particularly in the spleen, most of which were functionally linked to erythrocyte development, in line with the impaired erythropoiesis observed (Extended Data Fig. 3). Crossing to Mavs−/− mice (Extended Data Fig. 2g) rescued the lethal phenotype of Adar1mZα/– mice, as Adar1mZα/–Mavs−/− animals appeared healthy, did not show upregulation of ISGs and reached adulthood without displaying signs of pathology at least up to the age of 15 weeks (Fig. 1a–e and Extended Data Fig. 2). Therefore, in agreement with recent reports6–8, hemizygous expression of ADAR1 with a mutated Zα domain induced a strong MDA5–MAVS-dependent type I IFN response, causing severe early postnatally lethal pathology in mice.
ZBP1 causes pathology in Adar1mZα/– mice
The finding that hemizygous expression of ADAR1 with a mutated Zα domain causes severe pathology in both humans and mice indicates that the capacity of ADAR1 to bind Z-RNA is critical to prevent pathogenic IFN responses, but the underlying mechanisms remain poorly understood. ZBP1 expression was strongly increased in tissues from Adar1mZα/– mice, in line with the pronounced upregulation of ISGs (Fig. 1f,g and Supplementary Table 2). We therefore reasoned that ZBP1 could be functionally involved in the pathology of Adar1mZα/– mice and addressed its role by generating and analysing Adar1mZα/–Zbp1−/− animals. Notably, ZBP1 deficiency largely prevented early postnatal lethality in Adar1mZα/– mice, with about 70% of Adar1mZα/–Zbp1−/− mice surviving at least up to the age of 15 weeks (Fig. 1a). Inspection of mice at P1 showed partially restored body weight as well as RBC, HGB and HCT values in Adar1mZα/–Zbp1−/− compared with Adar1mZα/– mice (Fig. 1b,c). Moreover, ZBP1 deficiency reduced the numbers of CC3+ cells and ameliorated the intestinal pathology of Adar1mZα/– mice (Fig. 1d and Extended Data Fig. 2a). To gain insight into the ZBP1-dependent mechanisms driving disease pathogenesis in Adar1mZα/– mice, we compared the gene expression profiles from Adar1mZα/– and Adar1mZα/–Zbp1−/− pups at P1 by RNA-seq. Principal-component analysis (PCA) of differentially expressed genes showed that Adar1mZα/–Zbp1−/− samples clustered distinctly between Adar1mZα/– and Adar1mZα/–Mavs−/− or Adar1mZα/WT samples (Fig. 1e, top). Moreover, comparison of the expression of the set of 93 ISGs found to be upregulated in all three tissues showed that ZBP1 deficiency significantly suppressed the IFN response in the spleen, lung and brain of Adar1mZα/– mice (Fig. 1e, bottom). However, ZBP1 deficiency did not prevent ISG expression and all pathological features of Adar1mZα/– mice as efficiently as MAVS knockout, suggesting that ZBP1 probably acts to augment the MDA5–MAVS-dependent pathogenic IFN response. Together, these results identified a critical role for ZBP1 in promoting type I IFN responses and the severe early postnatally lethal pathology caused by hemizygous expression of ADAR1 with a mutated Zα domain.
Adult Adar1mZα/–Zbp1−/− mice showed lower body weight as well as mildly reduced RBC, HGB and HCT values compared with littermate control animals, whereas Adar1mZα/–Mavs−/− and Adar1mZα/–Zbp1−/−Mavs−/− mice exhibited normal body weight and blood values (Fig. 2a,b and Extended Data Fig. 4a). Heterozygous MAVS knockout partially rescued the early postnatal lethality of Adar1mZα/– mice, with about 50% of Adar1mZα/–MavsWT/– mice surviving at least up to the age of 15 weeks, when they showed strongly diminished body weight as well as RBC, HGB and HCT values compared with control and Adar1mZα/–Mavs−/− mice (Fig. 2a–c and Extended Data Fig. 4a). Notably, additional loss of ZBP1 rescued the lethality and normalized the body weight and RBC, HGB and HCT values in Adar1mZα/–Zbp1−/−MavsWT/− mice (Fig. 2a–c and Extended Data Fig. 4a). Histological analysis of organs from 15-week-old mice showed severe glomerular mesangial sclerosis (MS) in kidneys from Adar1mZα/–MavsWT/− mice, characterized by deposition of extracellular matrix, complete obstruction of the glomerular capillary convolute and focal mesangiolysis, compared with the normal tissue architecture in control and Adar1mZα/–Mavs−/− mice (Fig. 2d). ZBP1 deficiency strongly ameliorated this sclerosing phenotype, as reflected by decreased deposition of extracellular matrix and patent capillary lumina in kidneys from Adar1mZα/–Zbp1−/−MavsWT/− and Adar1mZα/–Zbp1−/− mice (Fig. 2d). Moreover, Adar1mZα/–MavsWT/− mice showed signs of pericentral sinusoidal dilatation in the liver and mild hyperplasia with small numbers of dying cells in the small intestine, which were ameliorated by ZBP1 deficiency (Extended Data Fig. 4b). RNA-seq analysis identified 399 genes, mostly ISGs, that were upregulated in lungs from 15-week-old Adar1mZα/–MavsWT/− mice compared with Adar1mZα/WT and wild-type control mice (Extended Data Fig. 5 and Supplementary Table 3). Using this set of 399 ISGs, we compared the effect of ZBP1 deficiency alone or in combination with heterozygous or homozygous MAVS knockout on the IFN response. Adar1mZα/–Zbp1−/− mice clustered distinctly from Adar1mZα/–MavsWT/− mice and had an overall mildly reduced ISG signature, suggesting that ZBP1 deficiency had a stronger effect than MAVS heterozygosity in limiting the IFN response (Fig. 2e). Additional ZBP1 deficiency considerably suppressed ISG expression in Adar1mZα/–MavsWT/− mice, with Adar1mZα/–Zbp1−/−MavsWT/− mice clustering closer to wild-type animals than to Adar1mZα/–MavsWT/− animals (Fig. 2e). ISG expression was largely normalized in Adar1mZα/–Mavs−/− mice, although these animals showed small but statistically significant differences in expression compared with Adar1mZα/WT controls (Fig. 2e), indicating that MAVS-independent mechanisms also contribute to the IFN response. Interestingly, double deficiency of ZBP1 and MAVS could fully normalize the expression of ISGs, with expression in Adar1mZα/–Zbp1−/−Mavs−/− mice indistinguishable from that in Adar1mZα/WT or wild-type animals (Fig. 2e), suggesting that ZBP1 contributes to the ISG response also independently of MAVS.
ZBP1–RIPK3 function in Adar1−/− mice
On the basis of our findings in Adar1mZα/– mice, we reasoned that ZBP1 might also contribute to the severe pathology caused by complete ADAR1 deficiency. However, we did not observe any live Adar1−/−Zbp1−/− mice born from crosses of heterozygous animals, showing that ZBP1 deficiency was not sufficient to rescue the embryonic lethality of Adar1−/− mice (Extended Data Fig. 6a). Adar1−/−Mavs−/− and Adar1−/−Mda5−/− animals develop to term but die during the first postnatal days19,33, showing that MDA5–MAVS-independent signalling causes postnatal pathology in Adar1−/− mice. We therefore assessed whether ZBP1 deficiency might synergize with MAVS knockout to rescue the phenotype of Adar1−/− mice. Indeed, we found that about 40% of Adar1−/−Zbp1−/−Mavs−/− mice survived to adulthood, in contrast to Adar1−/−Mavs−/− mice that died shortly after birth (Fig. 2f and Extended Data Fig. 6b). The Adar1−/−Zbp1−/−Mavs−/− mice that survived to adulthood showed reduced body weight but appeared healthy at least until the age of 15 weeks (Extended Data Fig. 6b–d). Histological analysis of different organs did not identify apparent pathology, with only mild hyperplasia and small numbers of dying cells observed in the intestine of Adar1−/−Zbp1−/−Mavs−/− mice (Extended Data Fig. 6e). We reasoned that ZBP1 may cause MAVS-independent pathology in Adar1−/− mice by inducing RIPK3-mediated cell death. Indeed, RIPK3 deficiency alone or in combination with heterozygous knockout of the caspase-8 adaptor protein Fas-associated protein with death domain (FADD) mimicked the effect of ZBP1 deficiency, with about 40% of Adar1−/−Mavs−/−FaddWT/−Ripk3−/− and Adar1−/−Mavs−/−FaddWT/WTRipk3−/− mice surviving at least up to the age of 15 weeks (Fig. 2f). Thus, ZBP1–RIPK3-mediated signalling caused MAVS-independent pathology resulting in early postnatal lethality of Adar1−/−Mavs−/− mice. We then assessed whether ZBP1 could induce cell death in Adar1−/−Mavs−/− mouse embryonic fibroblasts (MEFs). Stimulation with IFNγ, which induced robust expression of ZBP1, did not cause cell death in Adar1−/−Mavs−/− or Mavs−/− MEFs (Extended Data Fig. 6f,g). However, treatment of IFNγ-prestimulated cells with a low amount of the protein translation inhibitor cycloheximide (CHX) caused increased cell death in Adar1−/−Mavs−/− compared with Mavs−/− MEFs, which was prevented by the absence of ZBP1 (Extended Data Fig. 6h). Immunoblot analysis showed that stimulation with IFNγ and treatment with CHX induced phosphorylation of MLKL and increased cleavage of caspase-8 in Adar1−/−Mavs−/− compared with Mavs−/− primary MEFs (Extended Data Fig. 6i). ZBP1 deficiency prevented the phosphorylation of MLKL and reduced the cleavage of caspase-8 in these cells (Extended Data Fig. 6i), suggesting that ZBP1 induces necroptosis and, to a lesser extent, apoptosis. In line with this, combined pharmacological inhibition of RIPK3 and caspases strongly reduced the IFNγ- and CHX-induced death of Adar1−/−Mavs−/− primary MEFs (Extended Data Fig. 6j). Although it remains unclear to what extent the ZBP1–RIPK3-dependent cell death induced in cells treated with CHX relates to the in vivo role of ZBP1–RIPK3 signalling in mediating the pathology of Adar1−/−Mavs−/− mice, we reason that CHX treatment might mimic the activation of protein kinase R (PKR) and resulting inhibition of protein translation in ADAR1-deficient cells7. Collectively, these results showed that ZBP1–RIPK3-dependent signalling promoted the MAVS-independent pathology of Adar1−/−Mavs−/− mice.
ZBP1 is not involved in Trex1−/− mice
ZBP1 is expressed at very low levels in most tissues under steady-state conditions, but its expression is strongly induced by IFNs. Loss of ADAR1 function could trigger ZBP1-dependent pathology by promoting IFN-inducible upregulation of ZBP1 expression and/or by increasing the abundance of a ZBP1 ligand. To assess whether ZBP1 upregulation functions broadly to drive IFN-dependent pathology, we used another mouse model of type I interferonopathy caused by deficiency in TREX1, a cytosolic 3ʹ–5ʹ DNA exonuclease found to be mutated in people with AGS, familial chilblain lupus (FCL) and systemic lupus erythematosus (SLE)34. TREX1 deficiency in mice triggers cytosolic DNA-induced cyclic GMP-AMP synthase (cGAS)–stimulator of interferon genes (STING)-dependent type I IFN responses, resulting in systemic inflammation primarily manifesting in severe myocarditis35–38. Heart tissues from Trex1−/− mice showed profound upregulation of ZBP1; however, Trex1−/−Zbp1−/− mice were indistinguishable from Trex1−/− and Trex1−/−Zbp1WT/− littermates in terms of survival, body weight, splenomegaly, heart inflammation and fibrosis (Extended Data Fig. 7a–f). Moreover, ZBP1 deficiency did not inhibit the upregulation of ISGs and inflammatory cytokines and chemokines in heart tissues of Trex1−/− mice (Extended Data Fig. 7c,g,h). Therefore, although its expression was strongly induced in tissues of Trex1−/− mice, ZBP1 did not contribute to the cytosolic DNA-induced IFN response and pathology caused by TREX1 deficiency, in contrast to its important role in promoting the phenotype caused by impaired ADAR1 function.
Impaired ERE RNA editing in Adar1mZα/– mice
The specific role of ZBP1 in the pathology caused by ADAR1 deficiency could be explained by the accumulation of Z-RNA ligands in the absence of ADAR1-dependent RNA editing. In support of this hypothesis, previous studies have shown that the Zα domain of ADAR1 is required for editing of RNAs derived from EREs and particularly short interspersed nuclear elements (SINEs) in mouse cells6,8,30, which we previously identified as possible double-stranded RNA (dsRNA) ligands activating ZBP1 (ref. 21). Analysis of spleen RNA-seq data showed that expression of ERE groups previously shown to have the highest number of complementary reads with the potential to generate dsRNA21, including LTR/ERVK, LINE/L1, SINE/Alu and SINE/B2, was strongly induced in Adar1mZα/– compared with Adar1mZα/WT pups (Fig. 3a). Interestingly, ZBP1 deficiency inhibited the upregulation of these ERE transcripts in Adar1mZα/–Zbp1−/− mice (Fig. 3a), reminiscent of its effect in suppressing ISG expression. These findings suggest that upregulation of EREs depends on IFN-mediated induction of gene expression, probably because these EREs reside near or within ISGs. We then assessed whether adenosine-to-inosine (A-to-I) RNA editing was affected in Adar1mZα/– and Adar1mZα/mZα compared with Adar1mZα/WT mice. Analysis of RNA-seq data from the spleen and brain showed a considerable loss of edited sites in Adar1mZα/– compared with Adar1mZα/WT mice, the majority of which were found in SINE-derived RNAs (Fig. 3b,c and Extended Data Fig. 8). Adar1mZα/mZα mice did not show an overall change in editing compared with Adar1mZα/WT mice (Fig. 3b and Extended Data Fig. 8). Notably, ZBP1 deficiency did not rescue the impaired RNA editing in spleen and brain tissues of Adar1mZα/– mice (Fig. 3b and Extended Data Fig. 8c), in contrast to its strong effect in normalizing the IFN response. Similarly, MAVS deficiency did not rescue the editing defect in Adar1mZα/– mice (Fig. 3b). Together, these results indicate that increased expression of ERE-derived transcripts together with overall diminished editing of repeat RNAs in Adar1mZα/– mice could lead to the accumulation of dsRNAs with the capacity to generate Z-RNA ligands activating ZBP1.
Zα domain-dependent role of ZBP1 in Adar1mZα/– mice
To address the functional role of endogenous Z-RNA sensing by ZBP1, we crossed Adar1mZα/– mice with Zbp1mZα/mZα mice expressing ZBP1 with both its Zα domains mutated21. ZBP1 Zα domain mutation substantially, albeit partially, rescued the early postnatal lethality of Adar1mZα/– mice, with about 50% of Adar1mZα/–Zbp1mZα/mZα mice surviving to the age of at least 15 weeks (Fig. 3d). Moreover, ZBP1 Zα domain mutation considerably restored body weight but did not substantially improve the impaired erythropoiesis in Adar1mZα/– pups (Fig. 3e,f). Comparison of lung RNA-seq data from newborn pups showed that ZBP1 Zα domain mutation suppressed the ISG response of Adar1mZα/– mice similarly to ZBP1 deficiency, with Adar1mZα/–Zbp1mZα/mZα mice clustering together with Adar1mZα/–Zbp1−/− mice (Fig. 3g). Moreover, qRT–PCR analysis showed reduced expression of a set of ISGs in spleen, lung and liver tissues from Adar1mZα/–Zbp1mZα/mZα compared with Adar1mZα/– mice at P1 (Extended Data Fig. 9a). Adult Adar1mZα/–Zbp1mZα/mZα mice appeared healthy but had reduced body weight and RBC, HGB and HCT levels compared with their littermate controls (Fig. 3h,i and Extended Data Fig. 9b). Histological analysis of tissues from 15-week-old mice showed signs of pericentral sinusoidal dilatation in the liver and mild hyperplasia with small numbers of dying cells in the intestine (Extended Data Fig. 9c). Furthermore, comparison of lung RNA-seq data from 15-week-old mice showed that ZBP1 Zα domain mutation suppressed ISG expression in Adar1mZα/– mice to the same extent as ZBP1 deficiency (Fig. 3j). Together, these results showed that Zα domain-dependent sensing of endogenous ligands, presumably Z-RNA, activates ZBP1-dependent signalling, promoting IFN responses and causing the severe postnatally lethal phenotype of Adar1mZα/– mice. However, Zα domain mutation conferred somewhat less protection in terms of mouse survival and could not substantially improve the impaired erythropoiesis of Adar1mZα/– mice compared with ZBP1 deficiency (Fig. 3d,f,i), suggesting that ZBP1 also exerts Zα domain-independent functions, as shown previously in viral infection and inflammation models21. The finding that ZBP1 deficiency or disruption of its Zα domains suppressed upregulation of ISG expression argues that ZBP1 promotes the IFN response in Adar1mZα/– mice. However, the reduction in ISG expression could also be secondary to rescue of tissue pathology. Therefore, to investigate whether ZBP1 regulates the IFN response independently of tissue pathology, we assessed the effect of ZBP1 deficiency or Zα domain disruption in Adar1mZα/mZα mice, which are healthy but have elevated ISG expression (Extended Data Fig. 1). Notably, ZBP1 deficiency or disruption of its Zα domains strongly, albeit incompletely, suppressed the expression of ISGs in Adar1mZα/mZα mice (Fig. 3k and Extended Data Fig. 9d). Therefore, Zα domain-dependent ZBP1 signalling promotes the IFN response induced by disruption of the ADAR1 Zα domain independently of tissue damage.
RIPK1- and RIPK3-independent role of ZBP1
We reasoned that ZBP1 might engage RIPK3-dependent signalling to cause the severe pathology of Adar1mZα/– mice, as was the case in Adar1−/−Mavs−/− mice. Unexpectedly however, Adar1mZα/–Ripk3−/− pups displayed early postnatal lethality as well as reduced body weight and RBC, HGB and HCT values, showing that RIPK3 knockout did not mimic the effect of ZBP1 deficiency (Fig. 4a–c). Furthermore, RNA-seq and qRT–PCR gene expression analysis showed that, in contrast to ZBP1 deficiency, RIPK3 knockout did not suppress ISG expression in lung, spleen and liver tissues from Adar1mZα/– mice (Fig. 4d and Extended Data Fig. 10). To further address the role of necroptosis, we generated Adar1mZα/–Mlkl−/− mice and found that MLKL deficiency also did not prevent early lethality and upregulation of ISG expression in lung tissues from Adar1mZα/– mice (Fig. 4a–c,e). Thus, ZBP1 caused the pathology in Adar1mZα/– mice independently of RIPK3–MLKL-dependent necroptosis. We then reasoned that FADD–caspase-8-mediated apoptosis could contribute to the ZBP1-dependent pathology. However, Adar1mZα/–Fadd−/−Mlkl−/− mice showed early postnatal lethality and impaired erythropoiesis as well as elevated ISG expression (Fig. 4a–c,e). In addition, combined deficiency in FADD and RIPK3 also did not rescue the early postnatal lethality of Adar1mZα/– mice (Fig. 4a–c). Thus, combined inhibition of FADD–caspase-8-dependent apoptosis and RIPK3–MLKL-dependent necroptosis could not mimic the effect of ZBP1 deficiency, suggesting that ZBP1 induces pathology independently of necroptosis and FADD–caspase-8-dependent apoptosis. ZBP1 has also been implicated in inducing inflammatory gene expression by engaging RIPK1 through a RHIM-dependent interaction39,40. To address the role of RIPK1, we used Ripk1mR/mR mice, which express RIPK1 with a mutated RHIM20. Because Ripk1mR/mR mice die perinatally owing to MLKL-dependent necroptosis20, we generated and analysed Adar1mZα/–Ripk1mR/mRMlkl−/− mice. Strikingly, Adar1mZα/–Ripk1mR/mRMlkl−/− mice also displayed early postnatal lethality and impaired erythropoiesis as well as elevated ISG expression similarly to Adar1mZα/– pups (Fig. 4a–c,e), demonstrating that combined inhibition of necroptosis and RIPK1-dependent signalling could not mimic the effect of ZBP1 deficiency. Furthermore, immunohistological analysis of intestinal tissue sections showed that neither the Ripk3−/−, Mlkl−/− or Fadd−/−Mlkl−/− genetic background nor the Ripk1mR/mRMlkl−/− genetic background could prevent intestinal epithelial cell death in Adar1mZα/– mice (Fig. 4f). Because MAVS deficiency completely prevented and ZBP1 knockout strongly inhibited cell death in the gut of newborn Adar1mZα/– mice (Fig. 1d), these results suggest that the death of intestinal epithelial cells is a consequence of the IFN response and occurs independently of RIPK1, RIPK3–MLKL-mediated necroptosis and FADD–caspase-8-mediated apoptosis.
Discussion
Our results showed that ZBP1 promoted type I IFN responses and the associated pathology in Adar1mZα/– mice independently of RIPK1-mediated signalling, RIPK3–MLKL-dependent necroptosis and FADD–caspase-8-mediated apoptosis. These findings are in contrast to the function of ZBP1 in Adar1−/−Mavs−/− mice, where it causes early postnatal lethality by inducing RIPK3-dependent signalling (Fig. 2f). Therefore, ZBP1 has a dual role in mice with impairedADAR1 function. On the one hand, it acts in a RIPK3-dependent manner to cause MAVS-independent pathology in Adar1−/− mice, probably by inducing necroptosis. On the other hand, it acts in a RIPK1- and RIPK3-independent manner to promote a MAVS-dependent pathogenic type I IFN response, causing early postnatal lethality in Adar1mZα/– mice. MAVS deficiency nearly completely normalized whereas ZBP1 deficiency partially rescued ISG expression and the pathology of Adar1mZα/– mice, suggesting that ZBP1 is induced downstream of MAVS and contributes to type I IFN activation and the associated pathologies. The mechanisms by which ZBP1 promotes type I IFN activation in Adar1mZα/– mice remain elusive at present. TIR domain-containing adaptor-inducing interferon-β (TRIF), which induces IFN responses downstream of the Toll-like receptors TLR3 and TLR4 (ref. 41), also contains a RHIM and could be implicated in driving IFN activation downstream of ZBP1. ZBP1 was recently reported to contribute to TRIF-induced caspase-8 activation and interleukin (IL)-1β release42. However, this specific function was mediated via RHIM-dependent interaction with RIPK1 and therefore should be inhibited in a Ripk1mR/mRMlkl−/− genetic background, which did not rescue type I IFN activation in Adar1mZα/– mice, arguing against the involvement of this particular signalling pathway. It is also possible that RIPK1, RIPK3 and TRIF contribute to ZBP1-dependent IFN activation in Adar1mZα/– mice in a functionally redundant manner; if this is the case, inactivation of all three proteins may be required to mimic the effect of ZBP1 deficiency. Notably, in contrast to its previously suggested role as a cytosolic DNA sensor inducing IFN activation43, ZBP1 was not required for the cGAS–STING-dependent IFN response in Trex1−/− mice, suggesting that it specifically functions to augment RNA-induced MDA5–MAVS-dependent IFN responses in Adar1mZα/– mice.
Taken together, our results identified Zα domain-dependent cross-talk between ADAR1 and ZBP1 that critically controls IFN responses to endogenous RNA. Our findings identify suppression of endogenous Z-RNA formation by ADAR1 as a key mechanism preventing aberrant activation of pathogenic IFN responses by ZBP1. Although it remains technically challenging to directly assess Z-RNA formation in living cells and tissues, our results suggest that impaired ADAR1-dependent editing of RNAs primarily derived from SINEs causes the accumulation of Z-RNA ligands activating ZBP1. Strikingly, our genetic studies showed that ZBP1 induced pathogenic IFN responses in Adar1mZα/– mice in a manner independent of RIPK1, RIPK3–MLKL-dependent necroptosis and FADD–caspase-8-dependent apoptosis, suggesting a new mechanism of action. Collectively, while the specific downstream molecular mechanisms remain to be elucidated, our results identified ZBP1 as a key driver of pathogenic type I IFN responses triggered by impaired ADAR1 function and suggest that ZBP1-dependent signalling could contribute to the pathogenesis of type I interferonopathies caused by ADAR1 mutations in humans.
Methods
Mice
Zbp1−/− (ref. 21), Zbp1mZα/mZα (ref. 21) and Ripk3−/− (ref. 44) mice have been described previously. Adar1−/− (Adartm1b(EUCOMM)Wtsi) mice were generated from the EUCOMM (https://academic.oup.com/bfg/article/6/3/180/237263) line Adartm1a(EUCOMM)Wtsi using CMV:Cre deleter mice45. Adar1mZα mice, in which amino acids N175 and Y179 of the ADAR1 Zα domain were mutated to aspartic acid and alanine, respectively, were generated using CRISPR–Cas12a technology with all components purchased from Integrated DNA Technologies. Cas12a guide RNA (4 µM; 5′-CAGGGAGTACAAAATACGATTGA-3′; AsCas12a crRNA) targeting exon 2 of the Adar1 gene and 10 µM single-stranded DNA repair oligonucleotide (5′-A*G*G*TTTCCCCCTTCCTCTGTGCAGCTTTCCCTTCTTcTCCAGGGAagcCAAAATACGgTcGATGTCCCTTTTGGGGATTCTGAGCTCTCTGGCTAGCACATGGGCAG*T*G*G-3′; IDT, custom-made ultramer) with three phosphorothioate bonds at both ends (indicated by an asterisk) were co-electroporated essentially as described previously46 with 4 µM AsCas12a protein and 4 µM DNA-based Cas12a electroporation enhancer into C57BL/6N zygotes. Correct exchange of the nucleotides, represented in the repair oligonucleotide with lower-case letters, was assessed by Sanger sequencing in the resulting F0 mice. Trex1−/− and Mavs−/− mice were generated using CRISPR–Cas9 technology. Of note, Trex1 is a single-exon gene. For Trex1−/− mice, two sgRNAs (5′-TTCCAGGTCTAAGAAGATGA-3′ and 5′-CCTGGGCAGTAAGTCAAGAG-3′), each at 4 µM, in complex with 4 µM Cas9 protein (IDT) were co-electroporated into fertilized oocytes. Deletion of the Trex1 exon between the two sgRNAs was confirmed using primers 5′-ATCCCACTAGAACAACCCTGCC-3′ and 5′-TTCAGACTCCGCACCCTCATTT-3′ as well as by immunoblot analysis. For Mavs−/− mice, two sgRNAs (5′-CCGGTTCCCGATCTGCCTGT-3′ and 5′-ATACTGTGACCCCAGACAAG-3′) targeting exons 3 and 6, respectively, were co-injected into fertilized C57BL/6N oocytes at 50 ng µl–1 together with 100 ng µl–1 Cas9 mRNA (Trilink). Successful deletion of the critical exons was confirmed using PCR primers 5′-TTGATCCTCACACCGTACTTG-3′ and 5′-GTATTGTGTTGGCAGGTGCTT-3′. Mice used in this study were maintained in the animal facility of the CECAD Research Center, University of Cologne, in individually ventilated cages (Tecniplast, Greenline GM500) at 22 °C (±2 °C) and a relative humidity of 55% (±5%) under a 12-h light/12-h dark cycle on sterilized bedding (Aspen wood, Abedd) with access to a sterilized commercial pelleted diet (Ssniff Spezialdiäten) and acidified water ad libitum. The microbiological status of the mice was examined as recommended by the Federation of European Laboratory Animal Science Associations (FELASA), and the mice were free of all listed pathogens. All animal procedures were conducted in accordance with European, national and institutional guidelines, and protocols were approved by local government authorities (Landesamt für Natur, Umwelt und Verbraucherschutz Nordrhein-Westfalen). Animals requiring medical attention were provided with appropriate care and were killed when they reached predetermined criteria of disease severity. No other exclusion criteria existed. Experimental groups were not randomized as mice were assigned to groups on the basis of genotype. Sample size was estimated on the basis of previous experience. Female and male mice of the indicated genotypes were assigned to groups at random. Mice were analysed at the age stated in the respective figure legends. Mouse studies as well as immunohistochemical assessment of pathology were performed in a blinded fashion. Whole blood samples of the mice were analysed using Abacus Junior Vet (Diatron).
Immunoblotting
Protein extracts from organs were prepared using a beadmill (Precellys 24) in RIPA buffer supplemented with cOmplete protease inhibitor cocktail (Roche, 04693124001) and phosSTOP phosphatase inhibitor tablets (Roche, 4906837001) and denatured in 2× Laemmli buffer (Bio-Rad, 34095) supplemented with 5% β-mercaptoethanol. Cell lysates were prepared by direct cell lysis in RIPA buffer or IP buffer (20 mM Tris pH 7.4, 150 mM NaCl, 2 mM EDTA, 1% Triton X-100), supplemented with protease and phosphatase inhibitors, followed by denaturation in Laemmli buffer. Lysates were separated by SDS–PAGE, transferred to Immobilon-P PVDF membranes (Millipore, 05317) and analysed by immunoblotting with primary antibodies against ISG15 (Cell Signaling, 2743), p-STAT1 (Cell Signaling, 9167), STAT1 (Cell Signaling, 9172), ZBP1 (Adipogen, AG-20B-0010, or custom made), TREX1 (Santa Cruz, sc-133112), GAPDH (Novus Biologicals, NB300-221), ADAR1 (Santa Cruz, sc-73408), MLKL (Millipore, MABC604), p-MLKL (Cell Signaling, 37333), caspase-8 (Cell Signaling, 4790, or Alexis, ALX-804-447), cleaved caspase-8 (Cell Signaling, 8592) and α-tubulin (Sigma, T6074). Secondary horseradish peroxidase (HRP)-coupled antibodies against rat (Jackson ImmunoResearch, 112-035-003), rabbit (Amersham Pharmacia, NA934V) or mouse (Amersham Pharmacia, NA931V) were used to detect proteins using chemiluminescence with ECL SuperSignal West PicoPlus chemiluminescent substrate (Thermo Scientific, 34578), and signal was measured with a Fusion Solo X system (Vilber).
Cell death assays
Primary MEFs were maintained at 37 °C and 5% CO2 in DMEM (ThermoFisher, 41965-039) supplemented with 10% FCS (Biosell), 1% penicillin-streptomycin (ThermoFisher Scientific, 15140130), 1% l-glutamine (ThermoFisher Scientific, 25030-123) and 1 mM sodium pyruvate (ThermoFisher Scientific, 11360). For cell death assays, cells were seeded in 96-well plates at a density of 1 × 104 cells per well. The next day, cells were stimulated with 103 U ml−1 IFNγ (ImmunoTools, 12343537) for 48 h or 24 h followed by treatment with combinations of 1 μM CHX (Sigma, 239763), 10 μM Q-VD-OPh (R&D, OPH001) and 3 μM GSK'872 (Sigma, 5303890001) in the presence of 0.1 μM DRAQ7 (Biostatus, DR71000). Cells were imaged for the indicated duration of time in 2-h intervals using the IncuCyte S3 live-cell imaging and analysis platform (Essen BioScience) in bright-field and red fluorescence(emission, 635 nm; excitation, 585 nm) mode. DRAQ7-positive cells were automatically counted as dead cells in two to four images per well, and counts were averaged using the Incucyte software package version 2019B rev2.
Immunohistochemistry and histology
Tissue samples from mice were fixed in 4% paraformaldehyde (PFA) and embedded in paraffin. Sections of 5 µm were subjected to histological analysis by haematoxylin and eosin (H&E) staining or Masson’s Trichrome staining. For immunohistochemical analysis, slides were rehydrated and incubated with peroxidase blocking buffer (0.04 M sodium citrate, 0.121 M Na2HPO2, 0.03 M NaN3, 3% H2O2) for 15 min. Slides were washed and antigen retrieval was performed by digestion with 10 µg ml–1 proteinase K (Life Technologies, 25530031) for 5 min in TEX buffer (50 mM Tris, 1 mM EDTA, 0.5% Triton X-100, pH 8.0) for CD45 and F4/80 staining or in citrate Tris buffer (pH 6) in a pressure cooker for CD3 and CC3 staining. Sections were blocked for 60 min and incubated with the primary antibody for CD45 (clone 30 F-11; eBioscience, 14-0451), CD3 (clone CD3-12; Bio-Rad, MCA1477), CC3 (clone D5B2; Cell signaling, 9661) or F4/80 (clone A3-1; AbD Serotec, MCA497) at 4 °C overnight. Sections were incubated with biotinylated anti-rat secondary antibody (Jackson ImmunoResearch, 112-065-003) or anti-rabbit secondary antibody (Invitrogen, B2770) for 60 min. Staining was visualized using the Vectastain Elite ABC-HRP kit (Vector Laboratories, VEC-PK-6100) and DAB substrate (Dako Omnis, GV82511-2, or Vector Laboratories, SK-4100). Sections were then counterstained with haematoxylin for staining of the nuclei, dehydrated and mounted with Entellan. Histological sections were scanned using a Nanozoomer S360 (Hamamatsu) slide scanner. Images were analysed and processed using the Omero software package (https://openmicroscopy.org) and NDP.view2 Viewing software (Hamamatsu).
Histological analysis of brains was conducted following standardized protocols at the Institute of Neuropathology, University Medical Center of Freiburg. Sections (4 μm thick) were processed and stained with H&E by standard laboratory procedures.
Immunohistochemical labelling was performed with an Autostainer Link 48 (Agilent), according to the manufacturer’s instructions. Primary antibodies against IBA1 (clone EPR16588; Abcam, ab178846) and MAC3 (clone M3/84; BD Biosciences, 550292) for (activated) macrophages and microglia, B220 for B cells (clone RA3-6B2; BD Biosciences, 553084), CD3 for T cells (clone CD3-12; Bio-Rad, MCA1477) and the corresponding secondary antibodies goat anti-rabbit IgG (H+L) (Southern Biotech, 4050-08; for IBA1) and goat anti-rat IgG (H+L) (Southern Biotech, 3050-08; for MAC3, B220 and CD3) were used.
Histopathological analysis
Histopathological evaluation of intestinal tissues was performed on 3-µm-thick H&E-stained sections of paraffin-embedded Swiss rolls of intestinal tissues, using a modified version of a previously described scoring system47. In brief, histopathology scores were composed of four parameters: epithelial hyperplasia, quantity and localization of tissue inflammation, epithelial cell death and epithelial injury. An ‘area factor’ for the fraction of affected tissue was assigned and multiplied by the respective parameter score (1, 0–25%; 2, 25–50%; 3, 50–75%; 4, 75–100%). If different severities for the same parameter were observed in the same sample, each area was judged individually and multiplied by the corresponding area factor. Area factors for a given sample always added up to 4. The histology score was calculated as the sum of all parameter scores multiplied by their area factors. The maximum score was 64. Scores and ulcer quantification were based on one Swiss roll section per mouse and were determined in a blinded fashion. Quantification of CC3+ cells was performed on histological sections immunostained with antibodies against CC3. The total number of CC3+ cells was divided by the number of crypts to show the average number in one crypt. Two hundred crypts for small intestine and at least 74 crypts for colon were analysed per mouse. Counting was performed in a blinded fashion.
Histological analysis of kidneys was performed by applying standardized protocols at the Institute of Surgical Pathology, University Medical Center of Freiburg. In brief, 2-µm microtome sections of formalin-fixed, paraffin-embedded tissue were used for PAS reaction staining with standardized diagnostic procedures. Whole kidney slides (WSI) were digitalized using a Ventana DP 200 slide scanner (Roche Diagnostics Deutschland) equipped with a ×40 objective. The MS index was assessed by applying a four-tiered scoring system (0–3; 0, <5%; 1, 6–25%; 2, 26–50%; 3, >50%). Further quantitative analysis of tuft areas and cells (nuclei) per tuft area was performed using QuPath v0.3.2 image analysis software48,49. At least 50 glomerular tufts per mouse were manually segmented by random sampling. Nucleus segmentation of individual tufts was performed by applying the built-in nucleus segmentation tool (QuPath). Histopathological evaluation and quantitative analysis were performed in a blinded fashion by an expert renal pathologist. For analysis of histology, an inverted Zeiss Axio Imager microscope equipped with an Axiocam colour camera, ×10, ×40 and ×100 objectives and a Ventana DP 200 slide scanner was used.
Gene expression analysis by qRT–PCR
Total RNA was extracted with either TRIzol reagent (Life Technologies, 15596018) and chloroform or the NucleoSpin RNA kit (Macherey-Nagel, 740955.50), according to the manufacturer’s instructions, followed by cDNA synthesis using the SuperScript III First-Strand Synthesis System (Life Technologies, 18080051) with subsequent treatment with RNase H (Invitrogen, AM2293) or the LunaScript RT SuperMix kit (New England Biolabs, E3010L). qRT–PCR was performed using TaqMan probes and TaqMan Gene Expression Master Mix (ThermoScientific, 4369016) or Luna Universal Probe qPCR Master Mix (New England Biolabs, M3004X) in a QuantStudio 5 Real-Time PCR System (ABI). Reactions were run in technical duplicates with Tbp as a reference gene. Relative expression of gene transcripts is shown using the 2−ΔCt method and is represented in dot plot graphs as mRNA expression values relative to the reference gene. The TaqMan probes used were as follows: Tbp (Mm00446973_m1), Tnf (Mm00443258_m1), Il1b (Mm00434228_m1), Il6 (Mm00446190_m1), Nppb (Mm01255770_g1), Col3a1 (Mm01254476_m1), Irf7 (Mm00516793_g1), Isg15 (Mm01705338_s1), Ifi44 (Mm00505670_m1), Oasl1 (Mm00455081_m1), Mx1 (Mm00487796_m1), Ccl2 (Mm00441242_m1), Cxcl10 (Mm00445235_m1), Ifit1 (Mm00515153_m1) and Zbp1 (Mm00457979_m1, Mm00457981_m1).
RNA-seq and data processing
RNA was prepared with the NucleoSpin RNA Mini kit for RNA purification (Macherey-Nagel, 740955.50). rRNA was depleted with rRNA Removal Mix–Gold. For lung RNA, library preparation was performed using the QuantSeq 3′ mRNA-Seq Library Prep Kit FWD for Illumina (Lexogen). QuantSeq libraries were sequenced on an Illumina NovaSeq 6000 sequencer using Illumina RTA v3.4.4 base-calling software. For spleen and brain RNA, stranded Illumina sequencing libraries were prepared with the TruSeq Stranded Total RNA kit (Illumina, 20020599), according to the manufacturer’s instructions, from rRNA-depleted RNA samples and submitted for PE100 sequencing using an Illumina NovaSeq 6000 sequencer, yielding ~50 million reads per sample. The quality of the resulting data was assessed using FastQC v0.11.8 (https://www.bioinformatics.babraham.ac.uk/projects/fastqc/), and reads were subsequently quality and adaptor trimmed using cutadapt (v3.4)50 with stringent settings to remove error-containing reads (‘-q 20 --max-n 0 --max-ee 1’). Remaining reads were passed to HISAT2 (v2.1.0)51 for strand-aware alignment, and strand-specific counts of uniquely mapping reads were prepared using featureCounts (within Subread v1.6.4; ref. 52) against Ensembl GRCh38.100 annotations. Additional unstranded counts were obtained with featureCounts against a database of repetitive elements previously prepared for GRCh38 (ref. 53) using reads unassigned to features during the previous step.
Differential expression analyses
DESeq2 (v1.22.1)54 within R was used for read count normalization, and downstream differential expression analysis and visualization were performed within Qlucore Omics Explorer v3.3 (Qlucore). Repeat region annotation, RNA-seq read mapping and counting were carried out as previously described21.
Gene functional annotation
Pathway analyses were performed using g:Profiler (https://biit.cs.ut.ee/gprofiler) with genes ordered by the degree of differential expression. P values were estimated by hypergeometric distribution tests and adjusted by multiple-testing correction using the g:SCS (set counts and sizes) algorithm, integral to the g:Profiler server55. ISGs were defined according to the Interferome v2.01 database56.
Detection and analysis of A-to-I editing
Read alignments were processed with samtools markdup57 to identify likely PCR duplicates within the sequenced libraries, and A-to-I editing was assessed using JACUSA2 (ref. 58) with settings to flag and exclude from analysis potential editing sites in close proximity to the start and end of reads, indel positions and splice sites, as well as sites within homopolymer runs of more than seven bases, using only primary alignments of properly paired, non-duplicate reads. Detected and differential A>G editing sites were filtered for Z score > 1.96, a depth of ≥10 reads, a minimum editing fraction of ≥1%, ≥2 replicates to display editing and exclude potential SNPs, and a maximum editing fraction of <50%. Additionally, for differential sites, a >2-fold difference was required between test and control sample groups. Sites obtained were assigned to genomic features using annotatr v1.16 within R59. Assessments of editing enrichment within repetitive elements were conducted with regioneR v1.22 within R60 using randomization-based permutation tests with 100 bootstraps. Graphs were generated with GraphPad Prism v9.
Statistical analysis
Data shown in graphs are the mean or mean ± s.e.m. A non-parametric Mann–Whitney test, one-way ANOVA with Tukey’s multiple-comparisons test or Kruskal–Wallis test corrected by Dunn’s multiple-comparisons test was performed. Survival curves were compared using the Gehan–Breslow–Wilcoxon test. All statistical analyses were performed with GraphPad Prism.
Reporting summary
Further information on research design is available in the Nature Research Reporting Summary linked to this paper.
Online content
Any methods, additional references, Nature Research reporting summaries, source data, extended data, supplementary information, acknowledgements, peer review information; details of author contributions and competing interests; and statements of data and code availability are available at 10.1038/s41586-022-04878-9.
Supplementary information
Acknowledgements
We thank E. Gareus, M. Hahn, J. Kuth, L. Elles, P. Roggan, E. Stade, C. Uthoff-Hachenberg, J. von Rhein, T. Wagner, K. Gräwe and A. Sammarco for technical assistance. We acknowledge support from the Cologne Center for Genomics for RNA-seq and the CECAD imaging facility for microscopy. We also thank A. Athanasiadis and A. Herbert for valuable discussions and V. Dixit (Genentech) for Ripk3−/− mice. Research reported in this publication was supported by funding from the European Research Council (ERC) under the European Union’s Horizon 2020 research and innovation programme (grant agreement no. 787826 to M. Pasparakis), the Deutsche Forschungsgemeinschaft (DFG, German Research Foundation, projects SFB1403 (project no. 414786233), SFB1399 (project No. 413326622), and CECAD (project no. 390661388) to M. Pasparakis, projects SCHE 2092/3-1, SCHE 2092/4-1 (RP9, CP2, CP3), CRU329 and SFB1453 (project No. 43198400) to C.S. and project no. 413517907 to M.D.), the Swiss National Science Foundation (SNSF, project no. 199310) to M.D. and the Francis Crick Institute (FC001099) to G.K. M.N. was supported by a Japan Society for the Promotion of Science Overseas Research Fellowship (grant no. 201860571) and a postdoctoral fellowship from the Alexander von Humboldt Foundation.
Extended data figures and tables
Source data
Author contributions
H.J., L.W., N.O. and M. Pasparakis conceived the study and designed the experiments. H.J. analysed Adar1mZα/– and Adar1−/− mice and conducted in vitro biochemical analyses. L.W. analysed Adar1mZα/mZα mice, performed and analysed qRT–PCR and cell death assays, and prepared RNA samples for RNA-seq. S.W. analysed Trex1−/− mice and performed CC3 staining in tissues from Adar1mZα/– mice. J.L. performed qRT–PCR assays, prepared RNA samples for RNA-seq and tissue samples for histology, and performed western blot and cell death experiments. M.N. performed western blot experiments, cell death assays and general histopathology analysis, as well as quantification of CC3+ cells in colon and small intestinal samples. G.G.K. analysed the histopathology of gut samples and quantified CC3+ cells in small intestinal samples. N.O. performed FACS analysis, analysed Trex1−/− mice and prepared tissue samples. V.K. analysed liver histopathology. M.R. and C.S. analysed kidney histopathology. M.D. and M. Prinz analysed brain histopathology. G.R.Y. and G.K. analysed RNA-seq data for gene and ERE expression and A-to-I RNA editing. L.W., N.O., S.E.T. and B.Z. designed and generated Adar1mZα/mZα and Trex1−/− mice. C.S., M. Prinz, G.K. and M. Pasparakis supervised the experiments. H.J., L.W., G.K. and M. Pasparakis interpreted data and wrote the paper.
Peer review
Peer review information
Nature thanks Andreas Linkermann, Seamus Martin and the other, anonymous, reviewer(s) for their contribution to the peer review of this work. Peer reviewer reports are available.
Funding
Open access funding provided by Universität zu Köln.
Data availability
RNA-seq data have been deposited in the ArrayExpress database at EMBL-EBI under accession numbers E-MTAB-10953, E-MTAB-11537 and E-MTAB-11540. Source data are provided with this paper.
Competing interests
The authors declare no competing interests.
Footnotes
Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
These authors contributed equally: Huipeng Jiao, Laurens Wachsmuth
Extended data
is available for this paper at 10.1038/s41586-022-04878-9.
Supplementary information
The online version contains supplementary material available at 10.1038/s41586-022-04878-9.
References
- 1.Song B, Shiromoto Y, Minakuchi M, Nishikura K. The role of RNA editing enzyme ADAR1 in human disease. Wiley Interdiscip. Rev. RNA. 2022;13:e1665. doi: 10.1002/wrna.1665. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 2.Rice GI, et al. Mutations in ADAR1 cause Aicardi–Goutieres syndrome associated with a type I interferon signature. Nat. Genet. 2012;44:1243–1248. doi: 10.1038/ng.2414. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 3.Livingston JH, et al. A type I interferon signature identifies bilateral striatal necrosis due to mutations in ADAR1. J. Med. Genet. 2014;51:76–82. doi: 10.1136/jmedgenet-2013-102038. [DOI] [PubMed] [Google Scholar]
- 4.Placido D, Brown BA, 2nd, Lowenhaupt K, Rich A, Athanasiadis A. A left-handed RNA double helix bound by the Zα domain of the RNA-editing enzyme ADAR1. Structure. 2007;15:395–404. doi: 10.1016/j.str.2007.03.001. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 5.Herbert A, et al. A Z-DNA binding domain present in the human editing enzyme, double-stranded RNA adenosine deaminase. Proc. Natl Acad. Sci. USA. 1997;94:8421–8426. doi: 10.1073/pnas.94.16.8421. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 6.de Reuver R, et al. ADAR1 interaction with Z-RNA promotes editing of endogenous double-stranded RNA and prevents MDA5-dependent immune activation. Cell Rep. 2021;36:109500. doi: 10.1016/j.celrep.2021.109500. [DOI] [PubMed] [Google Scholar]
- 7.Maurano M, et al. Protein kinase R and the integrated stress response drive immunopathology caused by mutations in the RNA deaminase ADAR1. Immunity. 2021;54:1948–1960. doi: 10.1016/j.immuni.2021.07.001. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 8.Nakahama T, et al. Mutations in the adenosine deaminase ADAR1 that prevent endogenous Z-RNA binding induce Aicardi–Goutieres-syndrome-like encephalopathy. Immunity. 2021;54:1976–1988. doi: 10.1016/j.immuni.2021.08.022. [DOI] [PubMed] [Google Scholar]
- 9.Schwartz T, Behlke J, Lowenhaupt K, Heinemann U, Rich A. Structure of the DLM-1–Z-DNA complex reveals a conserved family of Z-DNA-binding proteins. Nat. Struct. Biol. 2001;8:761–765. doi: 10.1038/nsb0901-761. [DOI] [PubMed] [Google Scholar]
- 10.Herbert A. Z-DNA and Z-RNA in human disease. Commun. Biol. 2019;2:7. doi: 10.1038/s42003-018-0237-x. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 11.Rich A, Zhang S. Timeline: Z-DNA: the long road to biological function. Nat. Rev. Genet. 2003;4:566–572. doi: 10.1038/nrg1115. [DOI] [PubMed] [Google Scholar]
- 12.Wang AH, et al. Molecular structure of a left-handed double helical DNA fragment at atomic resolution. Nature. 1979;282:680–686. doi: 10.1038/282680a0. [DOI] [PubMed] [Google Scholar]
- 13.Hall K, Cruz P, Tinoco I, Jr, Jovin TM, van de Sande JH. ‘Z-RNA’—a left-handed RNA double helix. Nature. 1984;311:584–586. doi: 10.1038/311584a0. [DOI] [PubMed] [Google Scholar]
- 14.Athanasiadis A. Zα-domains: at the intersection between RNA editing and innate immunity. Semin. Cell Dev. Biol. 2012;23:275–280. doi: 10.1016/j.semcdb.2011.11.001. [DOI] [PubMed] [Google Scholar]
- 15.Brown BA, 2nd, Lowenhaupt K, Wilbert CM, Hanlon EB, Rich A. The Zα domain of the editing enzyme dsRNA adenosine deaminase binds left-handed Z-RNA as well as Z-DNA. Proc. Natl Acad. Sci. USA. 2000;97:13532–13536. doi: 10.1073/pnas.240464097. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 16.Ahmad S, et al. Breaching self-tolerance to Alu duplex RNA underlies MDA5-mediated inflammation. Cell. 2018;172:797–810. doi: 10.1016/j.cell.2017.12.016. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 17.Athanasiadis A, Rich A, Maas S. Widespread A-to-I RNA editing of Alu-containing mRNAs in the human transcriptome. PLoS Biol. 2004;2:e391. doi: 10.1371/journal.pbio.0020391. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 18.Liddicoat BJ, et al. RNA editing by ADAR1 prevents MDA5 sensing of endogenous dsRNA as nonself. Science. 2015;349:1115–1120. doi: 10.1126/science.aac7049. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 19.Pestal K, et al. Isoforms of RNA-editing enzyme ADAR1 independently control nucleic acid sensor MDA5-driven autoimmunity and multi-organ development. Immunity. 2015;43:933–944. doi: 10.1016/j.immuni.2015.11.001. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 20.Lin J, et al. RIPK1 counteracts ZBP1-mediated necroptosis to inhibit inflammation. Nature. 2016;540:124–128. doi: 10.1038/nature20558. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 21.Jiao H, et al. Z-nucleic-acid sensing triggers ZBP1-dependent necroptosis and inflammation. Nature. 2020;580:391–395. doi: 10.1038/s41586-020-2129-8. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 22.Koehler H, et al. Vaccinia virus E3 prevents sensing of Z-RNA to block ZBP1-dependent necroptosis. Cell Host Microbe. 2021;29:1266–1276. doi: 10.1016/j.chom.2021.05.009. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 23.Wang R, et al. Gut stem cell necroptosis by genome instability triggers bowel inflammation. Nature. 2020;580:386–390. doi: 10.1038/s41586-020-2127-x. [DOI] [PubMed] [Google Scholar]
- 24.Devos M, et al. Sensing of endogenous nucleic acids by ZBP1 induces keratinocyte necroptosis and skin inflammation. J. Exp. Med. 2020;217:e20191913. doi: 10.1084/jem.20191913. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 25.Zhang T, et al. Influenza virus Z-RNAs induce ZBP1-mediated necroptosis. Cell. 2020;180:1115–1129. doi: 10.1016/j.cell.2020.02.050. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 26.Maelfait J, et al. Sensing of viral and endogenous RNA by ZBP1/DAI induces necroptosis. EMBO J. 2017;36:2529–2543. doi: 10.15252/embj.201796476. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 27.Newton K, et al. RIPK1 inhibits ZBP1-driven necroptosis during development. Nature. 2016;540:129–133. doi: 10.1038/nature20559. [DOI] [PubMed] [Google Scholar]
- 28.Schade M, Turner CJ, Lowenhaupt K, Rich A, Herbert A. Structure–function analysis of the Z-DNA-binding domain Zα of dsRNA adenosine deaminase type I reveals similarity to the (α + β) family of helix-turn-helix proteins. EMBO J. 1999;18:470–479. doi: 10.1093/emboj/18.2.470. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 29.Feng S, et al. Alternate rRNA secondary structures as regulators of translation. Nat. Struct. Mol. Biol. 2011;18:169–176. doi: 10.1038/nsmb.1962. [DOI] [PubMed] [Google Scholar]
- 30.Tang Q, et al. Adenosine-to-inosine editing of endogenous Z-form RNA by the deaminase ADAR1 prevents spontaneous MAVS-dependent type I interferon responses. Immunity. 2021;54:1961–1975. doi: 10.1016/j.immuni.2021.08.011. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 31.Herbert A. Mendelian disease caused by variants affecting recognition of Z-DNA and Z-RNA by the Zα domain of the double-stranded RNA editing enzyme ADAR. Eur. J. Hum. Genet. 2020;28:114–117. doi: 10.1038/s41431-019-0458-6. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 32.Liddicoat BJ, et al. Adenosine-to-inosine RNA editing by ADAR1 is essential for normal murine erythropoiesis. Exp. Hematol. 2016;44:947–963. doi: 10.1016/j.exphem.2016.06.250. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 33.Mannion NM, et al. The RNA-editing enzyme ADAR1 controls innate immune responses to RNA. Cell Rep. 2014;9:1482–1494. doi: 10.1016/j.celrep.2014.10.041. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 34.Rodero MP, Crow YJ. Type I interferon-mediated monogenic autoinflammation: the type I interferonopathies, a conceptual overview. J. Exp. Med. 2016;213:2527–2538. doi: 10.1084/jem.20161596. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 35.Stetson DB, Ko JS, Heidmann T, Medzhitov R. Trex1 prevents cell-intrinsic initiation of autoimmunity. Cell. 2008;134:587–598. doi: 10.1016/j.cell.2008.06.032. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 36.Gall A, et al. Autoimmunity initiates in nonhematopoietic cells and progresses via lymphocytes in an interferon-dependent autoimmune disease. Immunity. 2012;36:120–131. doi: 10.1016/j.immuni.2011.11.018. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 37.Gray EE, Treuting PM, Woodward JJ, Stetson DB. Cutting edge: cGAS is required for lethal autoimmune disease in the Trex1-deficient mouse model of Aicardi–Goutieres syndrome. J. Immunol. 2015;195:1939–1943. doi: 10.4049/jimmunol.1500969. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 38.Ablasser A, et al. TREX1 deficiency triggers cell-autonomous immunity in a cGAS-dependent manner. J. Immunol. 2014;192:5993–5997. doi: 10.4049/jimmunol.1400737. [DOI] [PubMed] [Google Scholar]
- 39.Kaiser WJ, Upton JW, Mocarski ES. Receptor-interacting protein homotypic interaction motif-dependent control of NF-κB activation via the DNA-dependent activator of IFN regulatory factors. J. Immunol. 2008;181:6427–6434. doi: 10.4049/jimmunol.181.9.6427. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 40.Rebsamen M, et al. DAI/ZBP1 recruits RIP1 and RIP3 through RIP homotypic interaction motifs to activate NF-κB. EMBO Rep. 2009;10:916–922. doi: 10.1038/embor.2009.109. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 41.Ullah MO, Sweet MJ, Mansell A, Kellie S, Kobe B. TRIF-dependent TLR signaling, its functions in host defense and inflammation, and its potential as a therapeutic target. J. Leukoc. Biol. 2016;100:27–45. doi: 10.1189/jlb.2RI1115-531R. [DOI] [PubMed] [Google Scholar]
- 42.Muendlein HI, et al. ZBP1 promotes LPS-induced cell death and IL-1β release via RHIM-mediated interactions with RIPK1. Nat. Commun. 2021;12:86. doi: 10.1038/s41467-020-20357-z. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 43.Takaoka A, et al. DAI (DLM-1/ZBP1) is a cytosolic DNA sensor and an activator of innate immune response. Nature. 2007;448:501–505. doi: 10.1038/nature06013. [DOI] [PubMed] [Google Scholar]
- 44.Newton K, Sun X, Dixit VM. Kinase RIP3 is dispensable for normal NF-κBs, signaling by the B-cell and T-cell receptors, tumor necrosis factor receptor 1, and Toll-like receptors 2 and 4. Mol. Cell. Biol. 2004;24:1464–1469. doi: 10.1128/MCB.24.4.1464-1469.2004. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 45.Schwenk F, Baron U, Rajewsky K. A cre-transgenic mouse strain for the ubiquitous deletion of loxP-flanked gene segments including deletion in germ cells. Nucleic Acids Res. 1995;23:5080–5081. doi: 10.1093/nar/23.24.5080. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 46.Troder SE, et al. An optimized electroporation approach for efficient CRISPR/Cas9 genome editing in murine zygotes. PLoS ONE. 2018;13:e0196891. doi: 10.1371/journal.pone.0196891. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 47.Adolph TE, et al. Paneth cells as a site of origin for intestinal inflammation. Nature. 2013;503:272–276. doi: 10.1038/nature12599. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 48.Bankhead P, et al. QuPath: open source software for digital pathology image analysis. Sci. Rep. 2017;7:16878. doi: 10.1038/s41598-017-17204-5. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 49.Zimmerman SE, et al. Nephronectin regulates mesangial cell adhesion and behavior in glomeruli. J. Am. Soc. Nephrol. 2018;29:1128–1140. doi: 10.1681/ASN.2017070752. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 50.Martin M. Cutadapt removes adapter sequences from high-throughput sequencing reads. EMBnet.J. 2011;17:3. doi: 10.14806/ej.17.1.200. [DOI] [Google Scholar]
- 51.Kim D, Paggi JM, Park C, Bennett C, Salzberg SL. Graph-based genome alignment and genotyping with HISAT2 and HISAT-genotype. Nat. Biotechnol. 2019;37:907–915. doi: 10.1038/s41587-019-0201-4. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 52.Liao Y, Smyth GK, Shi W. featureCounts: an efficient general purpose program for assigning sequence reads to genomic features. Bioinformatics. 2014;30:923–930. doi: 10.1093/bioinformatics/btt656. [DOI] [PubMed] [Google Scholar]
- 53.Attig J, Young GR, Stoye JP, Kassiotis G. Physiological and pathological transcriptional activation of endogenous retroelements assessed by RNA-sequencing of B lymphocytes. Front. Microbiol. 2017;8:2489. doi: 10.3389/fmicb.2017.02489. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 54.Love MI, Huber W, Anders S. Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2. Genome Biol. 2014;15:550. doi: 10.1186/s13059-014-0550-8. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 55.Raudvere U, et al. g:Profiler: a web server for functional enrichment analysis and conversions of gene lists (2019 update) Nucleic Acids Res. 2019;47:W191–W198. doi: 10.1093/nar/gkz369. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 56.Rusinova I, et al. Interferome v2.0: an updated database of annotated interferon-regulated genes. Nucleic Acids Res. 2013;41:D1040–D1046. doi: 10.1093/nar/gks1215. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 57.Li H. A statistical framework for SNP calling, mutation discovery, association mapping and population genetical parameter estimation from sequencing data. Bioinformatics. 2011;27:2987–2993. doi: 10.1093/bioinformatics/btr509. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 58.Piechotta, M., Naarmann-de Vries, I. S., Wang, Q., Altmuller, J. & Dieterich, C. RNA modification mapping with JACUSA2. Genome Biol.23, 115 (2022). [DOI] [PMC free article] [PubMed]
- 59.Cavalcante RG, Sartor MA. annotatr: genomic regions in context. Bioinformatics. 2017;33:2381–2383. doi: 10.1093/bioinformatics/btx183. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 60.Gel B, et al. regioneR: an R/Bioconductor package for the association analysis of genomic regions based on permutation tests. Bioinformatics. 2016;32:289–291. doi: 10.1093/bioinformatics/btv562. [DOI] [PMC free article] [PubMed] [Google Scholar]
Associated Data
This section collects any data citations, data availability statements, or supplementary materials included in this article.
Supplementary Materials
Data Availability Statement
RNA-seq data have been deposited in the ArrayExpress database at EMBL-EBI under accession numbers E-MTAB-10953, E-MTAB-11537 and E-MTAB-11540. Source data are provided with this paper.